Alimera Sciences Closes $5 Million in Extended Series C...(scription ophthalmic pharmaceuticals. P...)

Date:8/27/2009

scription ophthalmic pharmaceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(R), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has acquired options to exclusive, worldwide licenses for two classes of nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxidase inhibitors, which Alimera is studying as potential treatments for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy. Alimera has exercised its option to acquire a license with respect to one of these classes of NADPH oxidase inhibitors.

'/>"/>

SOURCE Alimera Sciences, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD
2. Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
3. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
4. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
5. PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry
6. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
7. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
8. Advanced Life Sciences Announces Second Quarter 2009 Financial Results and Financial Outlook
9. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
10. Ingenuitys Technology Powers BD Cell Pathways Tool on New BD Biosciences Website
11. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB